Navigation Links
Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Date:9/4/2013

60;

The BLA filings were supported by the GEMINI™ Studies, a four-study clinical program investigating vedolizumab in 2,700 patients in nearly 40 countries, making it the largest Phase 3 clinical trial program conducted to date simultaneously evaluating both CD and UC. Enrolled patients had failed at least one conventional therapy, including glucocorticoids, immunomodulators and/or a tumor necrosis factor-alpha (TNF-alpha) antagonists. TNF-alpha antagonist and conventional therapy failure patients included those with inadequate response (primary non-responders), loss of response (secondary non-responders) or those who were intolerant.

Phase 3 study results for vedolizumab were published recently in the New England Journal of Medicine.

About the GEMINI™ Studies
Announced in early 2009, the GEMINI™ Studies is a Phase 3 program evaluating the effect of vedolizumab on clinical response and remission (along with effect on mucosal healing in UC), and long-term safety in moderately to severely active CD and UC patients who had failed at least one conventional therapy or a TNF-alpha antagonist. The GEMINI program consists of four separate studies – a placebo-controlled induction and maintenance study in patients with UC (GEMINI I), a placebo-controlled induction and maintenance study in patients with CD (GEMINI II), a placebo-controlled induction study in patients with CD with prior TNF-alpha antagonist failure (GEMINI III) and an open-label long-term safety study in patients with either CD or UC (GEMINI LTS).

About Crohn's disease and ulcerative colitis
Crohn's disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease (IBD), which is marked by inflammation in the GI tract. CD can impact any part of the digestive tract and common symptoms may include abdominal pain, diarrhea, rectal bleeding, weight loss, and fever. UC impacts the large intestine
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
4. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
5. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
6. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
7. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
8. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
9. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
10. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
11. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 10, 2011 Life is unpredictable and can be even ... season, your runny nose, sneezing or itchy, watery eyes just ... Adventures contest on Facebook.  Allergy sufferers are invited to ... for a chance to win $5,000 toward a fun-filled adventure ...
... JACKSONVILLE, Fla., Aug. 10, 2011 MSC Care Management, ... care management solutions to the workers, compensation industry, introduces ... to help our customers manage patient care progress and ... to MSC customers, targets vital patient feedback on the ...
Cached Medicine Technology:Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 2Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 3Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 4MSC Monitors Patient Benchmarks on Behalf of Customers with MSC CareTrack 2
(Date:4/17/2014)... have identified the first genetic variant specifically associated ... accounting for around 10-15 per cent of all ... of the breast cancer sub-type, called invasive lobular ... causes of this particular kind of breast cancer, ... research, published today (Thursday) in the journal ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... A form of partial epilepsy associated with auditory and ... of brain development during early childhood, according to a ... Center (BIDMC). , Described in today,s Advance On-line issue ... the first genetic link between childhood brain development and ...
... can lessen stress when children get overwhelmed, experts say ... are nervous about the new school year can relax ... Experts at Duke University, in Durham, N.C., recommend mindfulness, ... children transition into the new school year and deal ...
... ... of Washington D.C. is business owner John Wahlquist of eMedicalSystems, Bremerton, Washington state. Author of ... unusual choice to retire his product and migrate his medical practices over to a new ... ...
... ... Reproduction Agency , ... (PRWEB) August 23, 2009 -- Steve Masler, CEO of The Donor Source International, LLC, a ... Donor Source of New England, that will focus on the New England Third-Party Reproduction market., ...
... , LOUISVILLE, Ky., Aug. 22 A top medical ... Legion and colleague veterans service organizations can play a key role ... national suicide prevention coordinator, in pointing to the 5,000 self-inflicted deaths ... of our responsibility to own up to that. There,s no reason ...
... poor prognosis in both blacks and whites after surgery, study ... the risk of prostate cancer recurrence in both black and ... suggesting obesity may be more significant for black men. , ... study senior author Dr. Stephen Freedland, an associate professor of ...
Cached Medicine News:Health News:Fragile period of childhood brain development could underlie epilepsy 2Health News:Soothe Back-to-School Anxiety, Teach Kids to Relax 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 3Health News:The American Legion Can Play Key Role in Vets' Suicide Prevention, Says VA 2Health News:Obesity Tied to Prostate Cancer Recurrence 2
Low pressure automatic tourniquet with manual time. Includes extension hose and spiral replacement hose....
... Safety. Convenience. Reliability. Cost. These are the ... personnel, and administrators. With a special focus ... practical elements of todays technology to develop ... The A.T.S. 2000 Tourniquet uses ambient air ...
... Retractor System has been designed so the ... delicate soft tissue away from the operative ... the procedure without stay-sutures or assistance. This ... the freedom to do other tasks, which ...
... Battery System is a revolutionary new addition ... surgical instruments. The PowerPro Battery System is ... powered instrument available on the market. It ... designed to meet the requirements of large ...
Medicine Products: